Status:
COMPLETED
Enhancing Neuroplasticity and Frontal Lobe Function in Patients With Mild Alzheimer's Disease
Lead Sponsor:
Centre for Addiction and Mental Health
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
65+ years
Phase:
NA
Brief Summary
The purpose of this study is to determine if a novel brain stimulation approach using magnetic stimulation (Transcranial Magnetic Stimulation \[TMS\]) can improve memory and thinking processes in indi...
Detailed Description
In this study, the investigators aim at assessing and then enhancing neuroplasticity in the dorsolateral prefrontal cortex (DLPFC) and working memory - a key function of DLPFC - in patients with mild ...
Eligibility Criteria
Inclusion
- Inclusion Criteria for patients:
- Age 65 or above
- Meet NINCDS-ADRDA and DSM-IV TR criteria for a current diagnosis of Alzheimer's Disease
- Stable does of acetylcholinesterase inhibitors for at least 3 months
- Willingness and ability to speak English
- Willingness and ability to provide informed consent
- Corrected visual ability that enables reading of newspaper headlines and corrected hearing capacity that is adequate to respond to a raised conversational voice.
- Exclusion Criteria for patients:
- Meets criteria for an Axis I diagnosis within the past 12 months other than Dementia of the Alzheimer type.
- Mini Mental Status Examination score of 16 or less as described above
- Meets diagnostic criteria for current alcohol or other drug dependence within 6 months of testing
- Electroconvulsive Therapy (ECT) within 6 months of testing.
- Left handedness.
- Incompetency to consent
- Any contraindication for TMS
- Inclusion Criteria for healthy controls:
- Age 65 or above
- Willingness and ability to speak English
- Willingness and ability to provide informed consent
- Corrected visual ability that enables reading of newspaper headlines and corrected hearing capacity that is adequate to respond to a raised conversational voice.
- Exclusion Criteria for healthy controls:
- Meets criteria for an Axis I diagnosis other than simple phobias or adjustment disorder.
- Other neurological disorder affecting central nervous system.
- Psychotropic medication except for sedative /hypnotics at a stable dose for at least 4 weeks.
- Left handedness
- Any contraindication for TMS
Exclusion
Key Trial Info
Start Date :
April 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2017
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT01847586
Start Date
April 1 2013
End Date
October 1 2017
Last Update
January 24 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre for Addiction and Mental Health
Toronto, Ontario, Canada, M6J 1H4